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Introduction
Phosphodiesterase type 5 inhibitors (PDE5i) are powerful 
strong vasoactive drugs widely used to treat erectile dys-
function (ED) by the specific inhibition of PDE5 activity. 
3′,5′-Cyclic nucleotide phosphodiesterases (PDEs) are 
ubiquitous catalytic enzymes that cleave the phosphodies-
ter bonds in cyclic adenosine or guanosine monophosphate 
(cAMP and cGMP) to yield 5′-cyclic nucleotides (5′AMP, 
5′GMP). PDEs are a large family including at least 11 dif-
ferent isozymes (PDE1–PDE11), with highly conserved 
catalytic domain close to carboxy-terminal portion (C-ter-
minus) [1, 2]. They share common features, such as protein 
sequence, structure and enzymatic properties, inhibitor sen-
sitivity [2, 3].
The different families of mammalian PDEs are alter-
natively spliced in a tissue-specific manner and generate 
mRNAs and proteins with specific different regulatory 
properties. Multiple PDE isoforms are involved in creating 
heterogeneous cyclic nucleotide signaling within the cells 
[4, 5]. However, albeit some redundancy has been observed 
in cAMP and cGMP hydrolyzation, selective inhibitory 
activity has been identified on the basis of structural dif-
ferences among domains: PDE5, 6 and 9 are specific for 
cGMP cleavage, whereas PDE4, 7 and 8 are cAMP spe-
cific; subtypes 1, 2, 3, 10 and 11 are enzymatically active 
on both cyclic isotypes [6, 7].
This review aims to offer an overview onto the different 
clinical applications of PDE5i from past, when first hypoth-
esized for cardiovascular use, to present, mainly dedi-
cated to ED treatment, and future, potentially “renewed” 
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as therapeutic tools for cardiomyopathic disturbance and 
disease.
PDE subfamilies, tissue distribution and function
PDE1, also known as Calcium and calmodulin dependent 
phosphodiesterase, is widely distributed in different tissues 
and cells especially in brain areas and heart [8]. PDE2, which 
is expressed in various tissues—i.e., adrenal cortex, brain, 
corpus cavernosum, heart, kidney, liver, visceral smooth mus-
cle and skeletal muscle—hydrolyzes cGMP with higher affin-
ity than cAMP [8, 9]. PDE3 expression is high in adipocytes, 
pancreatic β-cells, platelets and vascular smooth muscle. 
PDE3 is clinically relevant because it regulates hemodynamic 
parameters, i.e., increases cardiac output and reduces left and 
right ventricular filling pressure, through direct enhancement 
of myocardial contractility [10, 11]. The subfamily of PDE4 
enzymes, specific for cAMP, is a therapeutic target for cen-
tral nervous system since these proteins, expressed especially 
in the brain, are involved in several processes, such as mood 
control, emesis and olfactory sensory transduction [8, 9, 12]. 
PDE6 (photoreceptor PDE) is the best-studied enzyme due 
to its important role in the signal transduction of light. Like 
all photoreceptor, it is expressed in the outer segments of the 
retinal photoreceptor neurons [9]. PDE7 is widely distributed 
in skeletal muscle and lymphocytes and has high affinity for 
cAMP but still little is known about its function and regula-
tion [8, 9]. PDE8 expression has been found particularly in 
testis, followed by other tissues (eye, liver, skeletal muscle, 
heart, 7 day embryo, kidney, ovary, and brain) [13]; it seems 
to be an important modulator for T effector cell functions 
and a regulator for T cell adhesion to vascular endothelium 
through the cAMP signaling pathway [14]. PDE9 is highly 
represented in kidney, spleen, lung, brain lymph node and 
thymus. It controls the activity of atrial natriuretic peptide 
(ANP) in excretory functions. PDE10 may be involved in the 
physiological regulation of motor and cognitive function [15]. 
Recent findings reveal that PDE11 expression is restricted in 
hippocampus and subiculum suggesting a potential specific 
role in mood and cognitive function [16].
After this summarized description of all the main types 
of PDEs, their localization and specific functions studied 
up to now, the topic of this paper will be addressed onto 
PDE5 function and, particularly, inhibition.
PDE5 tissue distribution, cellular expression 
and subcellular localization
PDE5 subtype is generated by one specific gene, PDE5A, 
on chromosome 4q 25–27, with three alternative spliced 
variants, PDE5A1, 5A2, 5A3, which differ at 5′ ends of 
mRNA and amine-terminal (N-terminus) [8]. All three 
human PDE5 isoforms share all known functional features 
such as phosphorylation site, allosteric cGMP-binding sites, 
catalytic domain. They also have similar biochemical prop-
erties regarding, i.e., cGMP binding, cGMP hydrolysis, and 
drug sensitivity [17]. PDE5 is present in virtually all cell 
types, tissue and organs; in particular, in humans PDE5 is 
expressed in lung, heart, penis, vagina, uterus, brain, pros-
tate, retina and platelets [17–29] with different and numerous 
functions up to the anatomical district, both in physiological 
and pathological conditions [17–29]. Concerning the latter 
ones, the inhibition of PDE5 activity can achieve different 
favorable effects, and, therefore, different clinical applica-
tions could be hypothesized [17–29], i.e., from urogenital 
diseases to neurodegenerative disorders, besides sexual dys-
function in male and females.
Table 1 summarizes tissue distribution and cell expres-
sion of PDE5 together with the possible specific clinical 
application of PDE5i.
Table 1  Tissue and cell distribution of PDE5. Potential clinical applications of PDE5i are depicted
Tissue distribution/cell expression Potential application of PDE5i
Heart/cardiomyocytes [21] Cardiac dysfunction (heart failure, ischemia/reperfusion injuries, 
infarct, ventricular arrhythmias, cardiopulmonary bypass)
Penis [17] Erectile dysfunction
Vagina/vessel smooth muscle, endothelial and epithelial cells [18, 22] Female sexual dysfunction
Uterus/myometrial cells [19, 22] Preterm labor
Brain/purkinje cells [24, 25] Psychiatric and neurodegenerative disorders
Prostate/endothelial and smooth muscle cells [26] Lower urinary tract symptoms
Urethra/ureteral smooth muscle [22] Ureteral colic
Bladder [22] Overactive bladder symptoms
Lung/pulmonary arteries, vascular smooth muscle cells [23] Pulmonary arterial hypertension
Platelets [27] Anti-platelet agents/inhibition of platelet aggregation
Retina/endothelial and smooth muscle cells of retina and choroids  
vessels, ganglion and bipolar cells [28, 29]
Regulation of ocular blood flow/retinal ischemic disease
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As from studies onto subcellular localization and func-
tion, PDE5 is mainly expressed and widely distributed in 
the cytoplasmic cell compartmentin myometrial cells, 
endothelial cells, smooth muscle cells of corpora cavernosa 
(CC) and peripheral blood mononuclear cells; in particular, 
in myometrial and endothelial cells, PDE5 distinct locali-
zation and accumulation in discrete vesicular compartment, 
corresponding to centrosomal area, may account for cGMP 
regulation during contraction [18–20].
PDE5 and ED
PDE5 is widely expressed in endothelial and smooth mus-
cle cells in penis corpora cavernosa where this specific sub-
type is 10–100-fold higher vs. other tissues [30] and spe-
cifically catalyzes cGMP.
PDE5 biomolecular mechanism
Penile erection is promoted by cGMP through vascular 
smooth muscle cells (VSMC) relaxation mediated by the 
action of nitric oxide (NO).
NO, released from both nonadrenergic noncholinergic 
nerve terminals and endothelial cells, diffuses into VSMC 
and promotes cGMP synthesis [8]. Cellular cGMP level 
in corpus cavernosum is primarily dictated by the bal-
ance between the cGMP synthesis, by guanylyl cyclases, 
and cGMP shut down, by PDE5. Whenever blood flow is 
decreased—i.e., due to structural or functional deterioration 
of the peripheral vascular bed and/or nerves; NO inadequate 
production by neurons and/or endothelium; cGMP excessive 
breakdown by PDE5; VSMC decreased compliance—penile 
connective tissue cGMP elevation may not be adequate to 
provide for a sufficient degree of penile tumescence, thereby 
resulting in ED [31, 32]. As PDE5 specific inhibitors block 
the PDE5 catalytic site, cGMP stabilization and accumula-
tion is enhanced and penile erection achieved [33, 34].
PDE5i pharmacokinetics and efficacy
Sildenafil, vardenafil, tadalafil and avanafil, the commer-
cialized PDE5i, are “competitive inhibitors” with cGMP 
for access to the catalytic site, but they do not interact with 
the nonhydrolytic allosteric cGMP-binding sites on PDE5 
[35–37].
All PDE5i retain different bioavailability, onset of action 
and pharmacokinetics profiles.
Plasma half-lives of sildenafil and vardenafil are similar, 
about 4 h, avanafil half-life is shorter, about 3 h, whereas 
tadalafil half-life is longer, 17.5 h [38, 39]. Sildenafil 
efficacy of action can last up to 12 h, similarly to varde-
nafil; tadalafil efficacy is maintained for up to 36 h, while 
avanafil has the shorter period of efficacy, with a maximal 
duration of action of 6 h [40, 41].
Those PDE5i reach the highest concentrations in plasma 
(Tmax) with different times. Tmax of 30–45 min for avanafil after 
dosing, indicating a rapid diffusion into the bloodstream when 
administered orally [42]; Tmax values of 60 min for sildenafil, 
vardenafil and 120 min for tadalafil [38]. All enzymes differ 
for 50 % inhibitory concentration (IC50): 4 nM sildenafil, 0.1–
0.4 nM vardenafil, 2 nM tadalafil and 4.3–5.2 nM avanafil [42]. 
Similar side effects are reported for all PDE5i, such as head-
ache (10–16 %), flushing (5–12 %), dyspepsia (4–12 %), nasal 
congestion (1–10 %), and dizziness (2–3 %) [43].
It is generally accepted that those differences in phar-
macokinetics could represent an advantage to choose and 
adjust the therapy on the basis of patient profile, interaction 
with some other drug(s) and evaluation of other aspects and 
components, either organic or psychic [44, 45]. However, 
the pharmacological properties and pharmacodynamic fea-
tures per se have been considered to be criteria not enough 
sufficient to establish a complete evaluation on PDE5i 
clinical efficacy: subjective parameters, such as psychom-
etry, patient’s preference, life quality or sexual life quality, 
also have to be included for a complete judgement on the 
effectiveness of this class of drugs [46]. Of interest, a good 
correlation between subjective parameters and objective 
biological measurements has been shown [45, 46]. On the 
basis of psychometric- and pharmacologic-related parame-
ters, all three PDE5i sildenafil, tadalafil and vardenafil have 
been defined “harmonious” as they enable penile erection 
in presence of sexual desire and attractiveness, as exten-
sively reported [46]. Correlating their relative “harmony” 
with pharmacokinetics helped to measure clinical therapeu-
tic outcome: no substantial dissimilarities have been found 
among the three molecules. The few differences existing, 
i.e., between sildenafil, tadalafil and vardenafil pharmacoki-
netics, make tadalafil—with a longer half-life—superior in 
number of sexual intercourse per pill, while vardenafil and 
sildenafil seem preferable when duration of erection, or vas-
cular efficacy and penile hardness are examined [46, 47].
So far, PDE5i have been demonstrated to retain a high 
specificity of action for ED treatment with an almost per-
fect tolerance profile.
PDE5i and coronary artery disease
Albeit now widely used and specifically licensed for ED, 
the first clinical target of PDE5 inhibition, in pioneering 
researches, was angina pectoris, in view of the specific 
isozyme activity and expression in smooth muscle cells 
and platelets, where PDE5 inhibition reduces aggregation 
[48]. The specific PDE5i sildenafil citrate, discovered in 
1989, was proposed for the treatment of coronary artery 
146 J Endocrinol Invest (2016) 39:143–151
1 3
disease (CAD) [49]. Those initial studies on sildenafil dem-
onstrated only marginal benefits due to little cardiovascu-
lar impact, although disappointing for CAD treatment, 
revealed interesting side effects in male subjects, as penile 
erection enhancement. Thereafter, further studies for this 
specific application led, in 1998, to the approval of silde-
nafil for ED treatment by the US Food and Drug Admin-
istration (FDA) [49]. As previously addressed, after silde-
nafil, other PDE5i, tadalafil (2003), vardenafil (2003) and, 
recently, avanafil (2012) have been developed and approved 
for ED treatment by FDA [50].
So far, for quite a long time, the use of PDE5i has been 
shifted away from cardiovascular applications, and it took 
nearly a decade after sildenafil first clinical introduction to 
“reallocate” this class of drugs for cardiovascular disorder 
treatment [48]. As previously stated, PDE5 expression is, 
indeed, largely diffuse in several types of tissues and cells 
connected with cardiovascular function, such as systemic 
arteries and veins, pulmonary arteries, cardiac and skeletal 
cells, platelets [21, 51–54].
Hence, basic and clinical studies started to focus onto 
vasoactive effects in tissues other than urological ones.
PDE5i and pulmonary arterial hypertension
Due to PDE5 high expression in lung vasculature, several 
lines of research started to investigate the effect of PDE5 
inhibition in pulmonary vascular endothelium and airway 
epithelium, in pulmonary arterial hypertension (PAH). 
PAH development and progression are strictly associ-
ated with endothelial dysfunction, vascular remodeling 
and fibrosis, finally leading to right heart failure. PDE5 
upregulation has been documented in remodeled pulmo-
nary artery during PAH [55] and, interestingly, PDE5 
inhibition has been shown to ameliorate pulmonary artery 
systolic and mean artery pressure, dyspnea score and gas 
transfer, pulmonary vascular resistance and cardiac out-
put, [56, 57].
It seems that circulating endothelial progenitor cell 
(EPC) is reduced in PAH patients [58, 59]. Remarkably, 
the treatment with sildenafil dose dependently rises EPC 
number [59]. Sildenafil-induced improvement in EPC 
number together with cGMP level stabilization is associ-
ated with lower mean pulmonary arterial pressure and 
higher cardiac index in PAH patients. Furthermore, the 
major vascular lesions in PAH are associated with abnor-
mal proliferation of VSMC, involved in the pathogenesis 
of intimal hyperplasia. As from in vitro experiments, silde-
nafil prevents the proliferation and increases the apoptosis 
of pulmonary artery smooth cells [55]. This effect seems 
specific for this cellular target since in other cell types as 
cardiomyocytes or skeletal muscle cells PDE5 inhibition 
exert an anti-apoptotic effect involving Bcl/Bax signaling 
[60–62].
Given the improvement of several hemodynamic and 
clinical parameters following PDE5 inhibition, sildenafil, 
in 2005, and, thereafter, tadalafil have been approved by 
the US FDA and became first-line therapies for PAH [63], 
primary or secondary to other connective tissue diseases, 
such as scleroderma (SSc) or systemic lupus erythematosus 
(SLE)—which share identical pathological changes in pul-
monary vessels [55].
PDE5i and cardiomyopathies
Remarkably, in addition to the favorable actions onto PAH, 
PDE5 inhibition exerts cardioprotective effects as docu-
mented in different cardiac pathologies: from heart failure 
(HF), where sildenafil improves cardiac kinetics [64], to 
ischemia/reperfusion injuries, where it ameliorates vascular 
perfusion/density and tissue blood flow, to infarct, where 
it reduces damage size, apoptotic processes and cardiac 
hypertrophy, to ventricular arrhythmias, where it reduces 
disease severity, to cardiopulmonary bypass, where it 
increases coronary blood flow and cardiac recovery [3, 60, 
61, 63].
Heart protection accomplishment by PDE5i is mainly 
attributed to the induced vasoactive effects linked to vascu-
lar tone regulation and release of endogenous cardioprotec-
tive molecules, such as adenosine, bradykinin and phenyle-
phrine from endothelial cells [6, 60]. This process is related 
to intracellular protein kinase (PK)C/ERK activation that, 
in turn, triggers a signaling cascade ending in endothelial/
inducible NO synthase (eNOS/iNOS) phosphorylation and 
NO release; following cGMP formation and stabilization, 
PGK activity is enhanced and results in opening KATP chan-
nel directly in mitochondria of cardiomyocytes [6]. A direct 
intramyocardial action of PDE5 inhibition seems to be sug-
gested also by the results obtained in diabetic dilative car-
diomyopathy after three-month treatment with 100 mg/day 
sildenafil: cardiac geometry and kinetics improved together 
with a decrease in circulating monocyte chemoattractant 
protein (MCP)-1 and tumor growth factor (TGF)-β, indepen-
dently of any other vasodilatory or endothelial effects [65].
PDE5i and tissue fibrosis
So far, it could be suggested that sildenafil efficacy in car-
dioprotection likely relies not only on vasodilation but 
seems, somehow, a direct effect maybe due to PDE5i-
induced antifibrotic action. The latter, in fact, seems to 
be related to a counter-regulation of the cytokine TGF-
β, which is considered an essential molecule for patho-
genic stromal reorganization ending in tissue fibrosis. A 
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deregulated TGF-β signaling is one of the driving events 
culminating to an altered tissue architecture reorganiza-
tion [66]. Some cytokines, indeed, like MCP-1, interleu-
kin (IL)-6 and TGF-β exert, either directly or indirectly, 
a decontrolled extracellular matrix (ECM) assessment 
and deposition, an altered fibroblast function and protein 
production—i.e., collagens, fibronectins or proteoglycans 
[67]—although the underlying mechanisms are part of 
a very complex network, not yet fully clarified. Further-
more, in vivo studies on fibrotic autoimmune diseases 
show that sildenafil exerts antifibrotic effects by inhibition 
of Rho kinase, a key effector for myofibroblast differentia-
tion [68]. Those observations are in line with the ability of 
the PDE5i vardenafil to inhibit and reverse the trans-dif-
ferentiation of primary human prostatic cells to myofibro-
blasts, that is reported to be associated with prostate stro-
mal remodeling and lower urinary tract symptoms (LUTS) 
in gland hyperplasia [69, 70]. In view of those effects, the 
use of sildenafil is also indicated to treat digital ischemic 
ulcers in Raynaud’s phenomenon secondary to SSc since 
it decreases frequency and duration of digital vasospasms 
attacks—although not specifically licensed for this indica-
tion [71, 72].
Fibrosis, as well known, is a “final” process result-
ing from the integration of vasculopathic/immunological 
processes and complex cell–cell dialogue, involving, as 
addressed before, several active mediators and cytokines 
responsible for the altered ECM deposition and hypertro-
phy. Several lines of investigation, i.e., have documented 
that cardiac fibrosis development derives from a tight inter-
action between cardiac fibroblasts and cardiomyocytes, 
via direct contacts or, indirectly, via paracrine factors [73, 
74]. This observation is in line with the emerging concept 
that cardiomyocytes and their complex communications 
with other nonmyocytes (from fibroblasts to endothelial or 
immune cells) play a pivotal role in heart pathogenesis and 
cardiomyopathy development [73–76].
Furthermore, based on data deriving from clinical to 
basic research, the central role of cardiac cells is likely par-
ticularly relevant since the early stages of cardiac diseases 
and not limited, i.e., to the final histopathological manifes-
tations, such as tissue fibrosis.
The model that sees cardiomyocytes as dynamically 
active cells and not simply passive targets in cardiomyopa-
thy is well in line with the emerging hypothesis that patho-
genesis of heart disease (but not only) derives from the per-
turbation of healthy conditions by immune/inflammatory 
events.
PDE5i and Th1‑driven inflammation
Nowadays, inflammation has been recognized as the 
common link occurring at the onset of several disorders 
affecting different tissues, including cardiac one. Grow-
ing evidence shows that the homeostatic balance between 
health and disease largely depends on the immune/inflam-
matory status and the associated biomolecular mediators. 
Since quite ago, it is known that anti-inflammatory agents 
may have clinical benefits in preventing cardiovascular dis-
ease, in view of the direct relation existing between mark-
ers of a general inflammatory status, like C-reactive pro-
tein, and the risk of cardiovascular diseases [77].
As research progresses, new evidences emerge on the 
pivotal role in cardiomyopathy initiation of fine-tuned 
immune processes, especially driven by pro-inflammatory 
T helper type 1 cells (Th1) and Th1 type-related molecules 
and cytokines. Those mechanisms and mediators have been 
depicted as important triggers for disease development at 
very early stages, when clinical signs are still not manifested. 
Thus, early changes of these specific immunoactive/inflam-
matory molecules, detected either in peripheral blood or 
at tissue level, could potentially mirror a shift from healthy 
to disease condition at time of disease onset or even before 
disease initiation. In this view, we have previously reported 
on the critical role of the highly chemoattractant cytokine, or 
chemokine, interferon (IFN)γ-induced 10 kDa protein, IP-10/
CXCL10 (C-X-C motif chemokine 10), in very early immune 
processes which elicit the inflammatory cascade, eventually 
culminating in cardiac homeostasis disturbance [78–80].
Chemokines are, indeed, a family of potent chemotactic 
small peptides known to drive and control leukocyte traf-
ficking during inflammatory conditions underlying several 
allo- and autoimmune disease [80, 81]. CXCL10, as the 
other CXC chemokines induced by IFNγ (CXCL9/Mig, 
or monokine induced by interferon gamma, and CXCL11/
ITAC, or interferon-inducible T cell alpha chemoattract-
ant) is deeply involved in mechanism(s) committed to initi-
ate and potentiate immune response, such as T cell prim-
ing [82]. Those Th1-related chemokines acting through 
their specific receptor CXCR3, expressed on T cell surface, 
retain the capacity to specifically address Th1 cell recruit-
ment to the critical tissue sites going toward alteration 
induced by inflammation.
Since the pioneering studies, by Hancock et al. on heart 
transplantation [83], CXCL10 neutralization per se seems 
enough to improve cardiac function and counteract heart 
rejection; thereafter, the pivotal role of CXCL10 has been 
confirmed in human heart transplantation [78, 79, 84] and 
recognized in human cardiac function and diseases, from 
myocarditis to cardiac pulmonary bypass or coronary artery 
disease [85–87]. Notably, CXCL10 has been proposed as 
an early pretransplant predictor of organ rejection [78, 84].
In addition, human cardiomyocytes under maximal 
inflammatory conditions express and secrete CXCL10 
besides other factors, i.e., IL-8, IL-6, virtually absent in 
basal normal conditions [75, 76, 86]. This observation is 
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in line with and supports the hypothesis that cardiomyo-
cytes act as active counterparts in inflammation-related 
dialogue among the different involved districts (systemic/
tissues) and cells (immune/tissue resident cells). Quite 
remarkably, inflammatory-induced CXCL10 release by 
human cardiac cells is targeted by some immunesuppres-
sors such as mycophenolate mofetil, or other drugs retain-
ing immunomodulatory activity, such as rosiglitazone or 
vitamin D receptor agonists [75, 76]. From our ongoing 
studies, this inhibitory effect onto CXCL10 release is 
also observed after the treatment with sildenafil of human 
cardiomyocytes maximally challenged by inflammation, 
while no effect has been found in basal condition (per-
sonal communication, Di Luigi et al., manuscript under 
revision, PlosOne 2015). This in vitro observation on the 
anti-inflammatory effect of PDE5i is consistent with the 
results obtained from in vivo studies in different patholo-
gies: PDE5i, with PDE4i and PDE7i, seem good candi-
dates as next generation treatments in inflammatory bowel 
disease [88]; tadalafil and vardenafil are capable to blunt 
inflammation-induced IL-8 secretion by human myofibro-
blast prostatic cells (hBPH) [70]; PDE5i attenuate experi-
mental autoimmune encephalomyelitis and experimental 
arthritis [55].
Conclusions
Thus, besides rehabilitation of ED, there is growing inter-
est in potential administration of PDE5i in several clini-
cal areas, i.e., from urology, for the relief of symptoms in 
prostate- and bladder-related disorders, to neurology, due 
to protection against ischemic injury, respiratory medicine, 
for the effect on pulmonary hemodynamics, and rheuma-
tology, as treatment for PAH or off-labeled treatment of 
Raynaud’s phenomenon in systemic scleroderma.
When evaluating PDE5i efficacy and clinical outcome in 
diseases other than sexual disturbance, such as cardiac dis-
eases, to attain a reliable evaluation, several variables have 
to be taken in account on the basis of the evidence, as pre-
viously addressed for ED.
That is to say, while isolated cardiovascular events 
and sudden deaths have been reported in early studies on 
PDE5i, successive larger placebo-controlled clinical trials 
and surveillance studies documented no greater risk of this 
class of drugs vs. placebo: the detrimental effects were due 
to the incorrect PDE5i use alongside the nitro compounds 
(NO-donors) and, thus, contraindication with nitrate use 
has been assessed. Moreover, studies on effectiveness show 
a better cardiovascular profile of sildenafil as compared to 
the other PDE5i [6].
Cardiovascular disease is often concomitant with sys-
temic inflammation and a deregulated status, as previously 
stated; in this light it is ingruing that sildenafil appears to 
be effective in un-balanced homeostasis conditions. This 
observation is consistent with a recent meta-analysis doc-
umenting that after sildenafil administration there are no 
hemodynamic effects in HF subjects with preserved ejec-
tion fraction while significant improvements have been 
achieved in HF patients with reduced ejection fraction [89, 
90].
PDE5i seem capable to counteract the release and activ-
ity of some biomolecular mediators responsible for elic-
iting the shift from healthy to disease condition. Those 
actions are likely to mirror, at least in part, the decrease 
induced by cGMP stabilization of Th1-related pro-inflam-
matory activity [55]. Indeed, protein kinase G (PKG) acti-
vation by cGMP seems responsible for negative remodeling 
in HF and cardiac hypertrophy blunting. Nevertheless, 
PDE5 expression is very low or even undetectable in nor-
mal myocardium [90, 91] while it is markedly upregulated 
under inflammation-related processes, such as oxidative 
stress and pressure overload hypertrophy [92–96].
Overall, PDE5i efficacy in cardiovascular disturbances 
likely relies on different effects on heart, such as attenua-
tion of adrenergic stimulation, reduction of ventricular-
vascular stiffening and maladaptive chamber remodeling, 
improvement of endothelial function and enhancement of 
renal responsiveness [97]. So far, we could speculate that 
PDE5i by reverting destabilized homeostatic conditions 
could exert a general “anti-inflammatory” action which 
could be potentially associated with clinical favorable 
outcome.
So far, altogether, those observations might reflect and, 
in some measure, explain the cardioprotective effects of 
PDE5i, as found in animal and human studies.
Undoubtedly, other investigations in vivo and in vitro 
as well are mandatory to confirm the beneficial effects of 
PDE5i in cardiomyopathies and, possibly, clearly elucidate 
the underlying biomolecular mechanism(s) as potential 
pharmacological target(s).
Our ongoing studies are, indeed, toward this direction, 
and aimed to evaluate PDE5i activity in vivo on circulat-
ing level of several Th1-related chemokines, first of all 
CXCL10, measured in early stages of cardiomyopathies 
and in vitro on different human cell types, such as endothe-
lial, cardiac and immune cells, to clarify the cellular targets. 
Of interest, an ongoing randomized, placebo-controlled, 
double-blind study (ClinicalTrial.gov, NCT01803828) 
enrolls diabetic females and males to evaluate PDE5i as 
new anti-remodeling drugs for early diagnosed and gender-
dependent cardiomyopathy.
Hopefully, once well integrated researches, both at clini-
cal and basic level, will offer strengthened and unambigu-
ous evidence on PDE5i as anti-inflammatory safe thera-
peutic tools, it is conceivable that this class of drug could 
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be licensed for the treatment or even prevention of cardiac 
diseases.
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